Chronic kidney disease (CKD) is an emerging non-communicable disease worldwide. The Arab countries have a high prevalence of CKD risk factors, e.g. diabetes, obesity and hypertension. Unfortunately, the magnitude of CKD in the Arab world has not been studied well. This review presents the current data on CKD in the Arab world and proposes a call for action to address this rising epidemic.

Keywords:
Chronic kidney disease, Diabetes, Hypertension, Obesity, Screening programs, Arab league, Arab world, Middle East
1.
Levey AS, Atkins R, Coresh J, Cohen EP, Collins AJ, Eckardt KU, Nahas ME, Jaber BL, Jadoul M, Levin A, Powe NR, Rossert J, Wheeler DC, Lameire N, Eknoyan G: Chronic kidney disease as a global public health problem: approaches and initiatives – a position statement from Kidney Disease Improving Global Outcomes. Kidney Int 2007;72:247–259. http://www.kdigo.org/pdf/Levey_KI_2007.pdf (accessed May 18, 2012).
2.
USRDS 2008 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, NIH, 2008.
3.
International Federation of Diabetes: Facts and figures. http://www.idf.org/home/index.cfm?node=6 (accessed March 17, 2009).
4.
WHO: Diabetes programme. http://www.who.int/diabetes/en/ (accessed March 17, 2009).
5.
Albach NM: Increased prevalence rate of diabetes mellitus and associated risk factors in the Arab world. Poster 1364, presented at the 18th International Diabetes Federation Congress, Paris, August 24–29, 2003.
6.
Ashour Z, Ibrahim MM, Appel LJ, Ibrahim AS, Whelton PK: The Egyptian National Hypertension Project (NHP): design and rationale – the NHP investigative team. Hypertension 1995;26:880–885.
7.
Ibrahim MM, Rizk H, Appel LJ, el Aroussy W, Helmy S, Sharaf Y, et al: Hypertension prevalence, awareness, treatment, and control in Egypt: results from the Egyptian National Hypertension Project (NHP) – NHP investigative team. Hypertension 1995;26:886–890.
8.
Afifi A, Karim MA: Renal replacement therapy in Egypt: first annual report of the Egyptian Society of Nephrology, 1996. East Mediterr Health J 1999;5:1023–1029.
9.
Al-Nozha MM, Ali MS, Osman AK: Arterial hypertension in Saudi Arabia. Ann Saudi Med 1997;17:170–174.
10.
Al-Nozha MM, Abdullah M, Arafah MR, Khalil MZ, Khan NB, Al-Mazrou YY, et al: Hypertension in Saudi Arabia. Saudi Med J 2007;28:77–84.
11.
El-Shahat YI, Bakir SZ, Farjou N, Hashim T, Bohaliga A, Al-Hossani H, et al: Hypertension in UAE citizens – preliminary results of a prospective study. Saudi J Kidney Dis Transpl 1999;10:376–381.
12.
Baynouna LM, Revel AD, Nagelkerke NJ, Jaber TM, Omar AO, Ahmed NM, et al: High prevalence of the cardiovascular risk factors in Al-Ain, United Arab Emirates: an emerging health care priority. Saudi Med J 2008;29:1173–1178.
13.
Maziak W, Rastam S, Mzayek F, Ward KD, Eissenberg T, Keil U: Cardiovascular health among adults in Syria: a model from developing countries. Ann Epidemiol 2007;17:713–720.
14.
Abdulle AM, Nagelkerke NJ, Abouchacra S, Pathan JY, Adem A, Obineche EN: Under-treatment and under diagnosis of hypertension: a serious problem in the United Arab Emirates. BMC Cardiovasc Disord 2006;6:24.
15.
Nazim Uddin K: Prevalence of hypertension in Saudi Arabia. Practitioner East Mediterr Ed 1994;11:805–806.
16.
Ferris M, Hogan SL, Chin H, Shoham DA, Gipson DS, Gibson K, et al. Obesity, albuminuria, and urinalysis findings in US young adults from the Add Health Wave III study. Clin J Am Soc Nephrol 2007;2:1207–1214.
17.
Elsayed EF, Sarnak MJ, Tighiouart H, Griffith JL, Kurth T, Salem DN, et al: Waist-to-hip ratio, body mass index, and subsequent kidney disease and death. Am J Kidney Dis 2008;52:29–38.
18.
Elsayed EF, Tighiouart H, Weiner DE, Griffith J, Salem D, Levey AS, et al: Waist-to-hip ratio and body mass index as risk factors for cardiovascular events in CKD. Am J Kidney Dis 2008;52:49–57.
19.
Foster MC, Hwang SJ, Larson MG, Lichtman JH, Parikh NI, Vasan RS, et al: Overweight, obesity, and the development of stage 3 CKD: the Framingham Heart Study. Am J Kidney Dis 2008;52:39–48.
20.
Alexander MP, Patel TV, Farag YM, Florez A, Rennke HG, Singh AK: Kidney pathological changes in metabolic syndrome: a cross-sectional study. Am J Kidney Dis 2009;53:751–759.
21.
WHO: Obesity: preventing and managing the global epidemic – report of a WHO consultation. Geneva, WHO, 2003.
22.
Diabetes in the Arab World. www.arabdiabetes.org (accessed March 17, 2009).
23.
al-Mahroos F, al-Roomi K: Overweight and obesity in the Arabian Peninsula: an overview. J R Soc Health 1999;119:251–253.
24.
Moyer VA: Screening for chronic kidney disease: US Preventive Services Task Force Recommendation Statement. Ann Intern Med 2012, E-pub ahead of print.
25.
Alsuwaida AO, Farag YM, Al Sayyari AA, Mousa D, Alhejaili F, Al-Harbi A, Housawi A, Mittal BV, Singh AK: Epidemiology of chronic kidney disease in the Kingdom of Saudi Arabia (SEEK-Saudi investigators) – a pilot study. Saudi J Kidney Dis Transpl 2010;21:1066–1072.
26.
Abolfotouh MA, Soliman LA, Mansour E, Farghaly M, El-Dawaiaty AA: Central obesity among adults in Egypt: prevalence and associated morbidity. East Mediterr Health J 2008;14:57–68.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.